Mission Therapeutics, MTX325, Parkinson’s Disease, USP30 Inhibitor, Phase 1b Clinical Trial, MTX325-101, Mitochondrial Quality Control, Mitophagy, Neurodegenerative Diseases,

CAMBRIDGE, UK, October 15, 2026 Mission Therapeutics Limited, a clinical-stage biotechnology company developing treatments designed to restore cellular health...